Skip to main content

Table 3 The dynamic changes in LV function 6 ±1 and 35 ± 6 months after revascularisation within groups of patients with and without significant improvement in LVEF

From: Prediction of long-term segmental and global functional recovery of hibernating myocardium after revascularisation based on low dose dobutamine and late gadolinium enhancement cardiovascular magnetic resonance

Responders

Baseline

6 ± 1 months

35 ± 6 months

Mean diff. ± SD***

Pvalue***

LV EDVI (ml/m 2 )

84 ±34

84 ±23

85 ±24

1.6 ±30

0.94

LV ESVI (ml/m 2 )

55 ±24

43 ±19*

41 ±18

14 ±15

<0.001

LV SV (ml)

67 ±24

83 ±20*

92 ±27

24 ±24

<0.001

LVEF (%)

36 ±8

51 ±11*

54 ±11**

17 ±8

<0.001

MV RF (%)

22 ±11

19 ±12

16 ±10

5.0 ±10

0.021

WMSI

1.8 ±0.4

1.4 ±0.4*

1.4 ±0.5

0.4 ±0.4

<0.001

Non-responders

     

LV EDVI (ml/m 2 )

116 ±29

109 ±24

124 ±31

8.1 ±28

0.445

LV ESVI (ml/m 2 )

77 ±24

70 ±19

82 ±26

4.6 ±21

0.575

LV SV (ml)

77 ±22

77 ±18

84 ±16

7 ±19

0.359

LVEF (%)

33 ±6

36 ±8*

35 ±5

1.3 ±3.8

0.113

MV RF (%)

21 ±14

19 ±7

21 ±13

0.4 ±18

0.859

WMSI

2.1 ±0.4

1.9 ±0.3*

2.1 ±0.3

0.03 ±0.3

0.779

  1. *LV parameters that differed significantly between the baseline and 6 ±1 month evaluations; **LV parameters that differed significantly between the 6 ±1 month and 35 ±6 month evaluations; ***p values and mean differences ±standard deviation (SD) were calculated for LV parameters assessed at baseline and at the end of the study period. Definitions of the terms and abbreviations are in the text.